Press Release Summary = Biotech and Healthcare Companies Present Potential Solutions to the Bird Flu
Press Release Body = Global Demand Supports Development of Avian Flu Treatments and Antiviral Drugs Biotech and Healthcare Companies Present Potential Solutions to the Bird Flu
POINT ROBERTS, WA, Delta B.C., April 03, 2006 - www.China-AsiaStocks.com (CAS) and www.BiotechIndustryStocks.com (BIS) , investor and industry news portals for the China-Asia and biotechnology sectors, feature "Global Demand Boosts Avian Flu Vaccine Market\", for investors and industry following developments in the vaccine market. Biotech and Healthcare companies: Bridgetech Holdings International Inc., Generex Biotech, AVI Biopharma Inc., Hemispherx Biopharma, Inc, Carrington Laboratories and Aethlon Medical, discuss unique approaches to this potential global dilemma and offer insight to possible solutions.
Dr. Carlton Turner, President and CEO of Carrington Laboratories gave an overview on the market, commenting that, "Policymakers from around the world are responding as best they can to the threat of an H5 Avian Flu pandemic. The challenge lies in trying to find the right antigen, producing enough of it to protect the world's population and then finding a way to deliver it to large populations efficiently."
Michael Chermak, CEO for Bridgetech Holdings International Inc (OTC.PK: BGTH), has provided insights with respect to the effect the Avian Flu has had on China's healthcare market, "The impact of the Avian Flu outbreak on the Chinese healthcare system has been profound. The resulting self examination has created a sense of urgency, regarding the modernization and improvement of the entire system."
Vice President of Generex (NASDAQ: GNBT) and President of Antigen Express, Dr. Eric Vonhofe, expressed great confidence in their product, explaining that," Last fall, the government paid about $100 million for an egg based vaccine, but that will probably be enough for only about 3 million people. In contrast, our vaccine which is synthetic can be made on a 100 kg scale quickly, efficiently and at a relatively inexpensive rate."
AVI Biopharma Inc., a producer of antiviral drugs, has established avian influenza H5N1 as a priority within the company. Michael Hubbard, Director of Investor Relations for the company said that, "We are moving as quickly as we can on Avian Flu, given the urgency. As soon as we have the safety data, we can apply for a new drug application with the FDA, which we hope to do before year's end." Dr. David Strayer, Medical Director at Hemispherx Biopharma, Inc. (AMEX: HEB) also pointed out that, "This area could move very rapidly because there is an urgent need for a better way to treat and prevent Avian influenza. I think there is great potential here for our company."
However, antiviral drugs currently being stockpiled as part of a global strategy to treat Avian Flu may have little therapeutic value once the deadly cytokine store has been triggered. As explained by James A. Joyce, Chairman and CEO at Aethlon Medican Inc. (OTCBB: AEMD), "Once a cytokine storm has been triggered, the Hemopurifier could serve as the first, and perhaps only option for treating H5N1 infected patients."
To Read "Global Demand Boosts Avian Flu Vaccine Market" In Full Click Here: http://www.China-AsiaStocks.com/Articles/Avian_Flu.asp
About our CAS and BIS Portals:
www.China-AsiaStocks.com and www.BiotechIndustryStocks.com portals within the InvestorIdeas.com content umbrella, offer investors research, news and links to public companies within the China-Asia and Biotechnology sectors. CAS and BIS do not make recommendations, but offer unique free information portals to research news, articles, interviews and a growing list of participating public companies in the China-Asia and biotech industry.
China-AsiaStocks.com includes a comprehensive and growing list of China Asia Stocks: http://www.China-AsiaStocks.com/Companies/China-AsiaStocks/Stocks_List.asp
To visit our China-Asia portal in Chinese click here: http://www.china-asiastocks.com/CAS/
Featured Sponsor Participating in the China Asia Market: (CAS is compensated by Bridgetech Holding International as disclosed in disclaimer.)
Bridgetech Holdings International Inc (OTC.PK: BGTH) a leading distributor of western based healthcare products and medical technology in China. For more info: http://www.china-asiastocks.com/CO/BGTH/Default.asp or visit the company\'s website at www.bthi.com.
Investorideas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by its \"featured companies.\" Bridgetech Holdings International, Inc five thousand dollars per month and ten thousand shares of 144 stock as a one time fee .Additionally , Aethlon Medical was a former featured company on Investorideas.com, please review previous clients disclaimer.
For More Information Contact:
Dawn Van Zant 800-665-0411 Fei Wang 866-948-0848 Email: dvanzant@investorideas.com or fwang@investorideas.com
Web Site: www.InvestorIdeas.com
Source: China-AsiaStocks.com, Bridgetech Holdings International, Generex Biotech, AVI Biopharma Inc., Hemispherx, Carrington Laboratories and Aethlon Medical
Web Site = http://www.china-asiastocks.com
Contact Details = Dawn Van Zant 800-665-0411 Fei Wang 866-948-0848 Email: dvanzant@investorideas.com or fwang@investorideas.com
2025
